TER
0.35% p.a.
Distribution policy
Accumulating
Replication
Full replication
Fund size
4 m
Holdings
53
Overview
Description
The VanEck Genomics and Healthcare Innovators UCITS ETF A seeks to track the MVIS Global Future Healthcare ESG index. The MVIS Global Future Healthcare ESG index tracks companies worldwide that are active in the genomics or e-healthcare industries. The stocks included are filtered according to ESG criteria (environmental, social and corporate governance).
Documents
Chart
Basics
Data
| Index | MVIS Global Future Healthcare ESG |
| Investment focus | Equity, World, Health Care, Social/Environmental |
| Fund size | GBP 4 m |
| Total expense ratio | 0.35% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | Yes |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in GBP) | 18.29% |
| Inception/ Listing Date | 2 September 2022 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | VanEck |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Fund Services (Ireland) Limited |
| Investment Advisor | VanEck Asset Management B.V. |
| Custodian Bank | State Street Custodial Services (Ireland) Limited |
| Revision Company | KPMG Ireland |
| Fiscal Year End | 31 December |
| Swiss representative | Zeidler Regulatory Services (Switzerland) AG |
| Swiss paying agent | Helvetische Bank AG |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Non-Tax Reporting Fund |
| UK | No UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | No |
| Securities lending counterparty |
Similar ETFs
This section provides you with information on other ETFs with a similar investment focus to the VanEck Genomics and Healthcare Innovators UCITS ETF A.
Similar ETFs via ETF search
Similar ETFs via investment guides
How do you like our ETF profile? Here you'll find our Questionnaire.
Holdings
Below you find information about the composition of the VanEck Genomics and Healthcare Innovators UCITS ETF A.
Top 10 Holdings
Weight of top 10 holdings
out of 53
56.31%
| Vertex Pharmaceuticals, Inc. | 7.63% |
| Regeneron Pharmaceuticals | 7.18% |
| Veeva Systems | 6.39% |
| DexCom | 5.72% |
| Illumina, Inc. | 5.59% |
| Moderna, Inc. | 5.32% |
| Alnylam Pharmaceuticals | 5.11% |
| BioNTech SE | 4.70% |
| Natera | 4.49% |
| Insulet | 4.18% |
Sectors
| Health Care | 89.05% |
| Consumer Discretionary | 4.68% |
| Consumer Staples | 0.94% |
| Other | 5.33% |
As of 30/09/2024
Performance
Returns overview
| YTD | -5.54% |
| 1 month | -3.64% |
| 3 months | -2.05% |
| 6 months | -3.32% |
| 1 year | +4.44% |
| 3 years | - |
| 5 years | - |
| Since inception (MAX) | -14.92% |
| 2023 | -9.98% |
| 2022 | - |
| 2021 | - |
| 2020 | - |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 18.29% |
| Volatility 3 years | - |
| Volatility 5 years | - |
| Return per risk 1 year | 0.24 |
| Return per risk 3 years | - |
| Return per risk 5 years | - |
| Maximum drawdown 1 year | -10.46% |
| Maximum drawdown 3 years | - |
| Maximum drawdown 5 years | - |
| Maximum drawdown since inception | -27.95% |
Rolling 1 year volatility
Stock exchange
Listings
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| Borsa Italiana | EUR | CURE | - - | - - | - |
| gettex | EUR | CURE | - - | - - | - |
| Borsa Italiana | EUR | - | CURE IM CUREUSIV | CURE.MI CUREINAV=SOLA | |
| London Stock Exchange | USD | CURE | CURE LN CUREUSIV | CURE.L CUREUSDINAV=SOLA | |
| London Stock Exchange | GBP | CURG | CURG LN CUREUSIV | CURG.L CUREUSDINAV=SOLA | |
| SIX Swiss Exchange | CHF | CURE | CURE SE CUREUSIV | CURE.S CUREUSDINAV=SOLA | |
| XETRA | EUR | CURE | CURE GY CUREUSIV | CURE.DE CUREINAV=SOLA |
Further information
Further ETFs with similar investment focus
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF | 989 | 0.40% p.a. | Accumulating | Sampling |
| Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |
Frequently asked questions
What is the name of CURE?
The name of CURE is VanEck Genomics and Healthcare Innovators UCITS ETF A.
What is the ticker of VanEck Genomics and Healthcare Innovators UCITS ETF A?
The primary ticker of VanEck Genomics and Healthcare Innovators UCITS ETF A is CURE.
What is the ISIN of VanEck Genomics and Healthcare Innovators UCITS ETF A?
The ISIN of VanEck Genomics and Healthcare Innovators UCITS ETF A is IE000B9PQW54.
What are the costs of VanEck Genomics and Healthcare Innovators UCITS ETF A?
The total expense ratio (TER) of VanEck Genomics and Healthcare Innovators UCITS ETF A amounts to 0.35% p.a.. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately. Please have a look at our article for more information about the cost of ETFs.
Is VanEck Genomics and Healthcare Innovators UCITS ETF A paying dividends?
VanEck Genomics and Healthcare Innovators UCITS ETF A is an accumulating ETF. This means that dividends are not distributed to investors. Instead, dividends are reinvested in the fund on the ex-date, which leads to an increase of the ETF's share price.
What's the fund size of VanEck Genomics and Healthcare Innovators UCITS ETF A?
The fund size of VanEck Genomics and Healthcare Innovators UCITS ETF A is 4m GBP. See the following article for more information about the size of ETFs.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.